title: Impact of antiretroviral medications on fasting lipid parameters.
abstract: It is widely accepted that metabolic disease in human immunodeficiency virus (HIV) develops at the intersection of traditional risk factors and HIV-specific contributors, but in observational studies it is difficult to dissect the contribution of the two. This review describes the metabolic impact of antiretroviral medications recommended in the first-line treatment in HIV-infected naive patients. At a clinical level, coronary heart disease screening and management will continue to be of paramount importance in the long-term management of HIV-positive patients on antiretroviral therapy.
authors.forename: Giovanni
authors.initials: G
authors.lastname: Guaraldi
authors.forename: Antonella
authors.initials: A
authors.lastname: Santoro
authors.forename: Chiara
authors.initials: C
authors.lastname: Stentarelli
authors.affiliation: Department of Medical and Surgical Sciences for Children and Adults, University of Modena and Reggio Emilia, Italy; Infectious Disease Clinic, Azienda USL 4 Prato, Italy.
authors.forename: Kety
authors.initials: K
authors.lastname: Luzi
mesh_terms: D000818:Animals; D044966:Anti-Retroviral Agents / Q000009:adverse effects*; D015415:Biomarkers / Q000097:blood; D003327:Coronary Disease / Q000097:blood / Q000209:etiology / Q000821:virology; D050171:Dyslipidemias / Q000097:blood / Q000139:chemically induced* / Q000188:drug therapy / Q000821:virology; D015658:HIV Infections / Q000097:blood / Q000188:drug therapy* / Q000821:virology; D020276:HIV Long-Term Survivors; D006801:Humans; D050356:Lipid Metabolism / Q000187:drug effects*; D008055:Lipids / Q000097:blood*; D011379:Prognosis; D012307:Risk Factors; D013997:Time Factors
chemical_list: D044966:Anti-Retroviral Agents; D015415:Biomarkers; D008055:Lipids